Literature DB >> 30882491

Integration of care for HIV and opioid use disorder.

Benjamin J Oldfield1,2,3, Nicolas Muñoz2, Mark P McGovern4, Melissa Funaro5, Merceditas Villanueva2,6, Jeanette M Tetrault2, E Jennifer Edelman2,6.   

Abstract

OBJECTIVE: We sought to identify optimal strategies for integrating HIV- and opioid use disorder-(OUD) screening and treatment in diverse settings.
DESIGN: Systematic review.
METHODS: We searched Ovid MEDLINE, PubMed, Embase, PsycINFO and preidentified websites. Studies were included if they were published in English on or after 2002 through May 2017, and evaluated interventions that integrated, at an organizational level, screening and/or treatment for HIV and OUD in any care setting in any country.
RESULTS: Twenty-nine articles met criteria for inclusion, including 23 unique studies: six took place in HIV care settings, 12 in opioid treatment settings, and five elsewhere. Eight involved screening strategies, 22 involved treatment strategies, and seven involved strategies that encompassed screening and treatment. Randomized controlled studies demonstrated low-to-moderate risk of bias and observational studies demonstrated fair to good quality. Studies in HIV care settings (n = 6) identified HIV-related and OUD-related clinical benefits with the use of buprenorphine/naloxone for OUD. No studies in HIV care settings focused on screening for OUD. Studies in opioid treatment settings (n = 12) identified improving HIV screening uptake and clinical benefits with antiretroviral therapy when provided on-site. Counseling intensity for OUD medication adherence or HIV-related risk reduction was not associated with clinical benefits.
CONCLUSION: Screening for HIV can be effectively delivered in opioid treatment settings, yet there is a need to identify optimal OUD screening strategies in HIV care settings. Strategies integrating the provision of medications for HIV and for OUD should be expanded and should not be contingent on resources available for behavioral interventions. REGISTRATION: A protocol for record eligibility was developed a priori and was registered in the PROSPERO database of systematic reviews (registration number CRD42017069314).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30882491      PMCID: PMC6588508          DOI: 10.1097/QAD.0000000000002125

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  81 in total

1.  "No more falling through the cracks": A qualitative study to inform measurement of integration of care of HIV and opioid use disorder.

Authors:  Benjamin J Oldfield; Nicolas Muñoz; Nicholas Boshnack; Robert Leavitt; Mark P McGovern; Merceditas Villanueva; Jeanette M Tetrault; E Jennifer Edelman
Journal:  J Subst Abuse Treat       Date:  2018-11-20

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

Review 3.  Office-Based Addiction Treatment in Primary Care: Approaches That Work.

Authors:  E Jennifer Edelman; Benjamin J Oldfield; Jeanette M Tetrault
Journal:  Med Clin North Am       Date:  2018-07       Impact factor: 5.456

4.  Health services utilization for people with HIV infection: comparison of a population targeted for outreach with the U.S. population in care.

Authors:  William E Cunningham; Nancy L Sohler; Carol Tobias; Mari-lynn Drainoni; Judith Bradford; Cynthia Davis; Howard J Cabral; Chinazo O Cunningham; Lois Eldred; Mitchell D Wong
Journal:  Med Care       Date:  2006-11       Impact factor: 2.983

5.  Reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research.

Authors:  C Pope; N Mays
Journal:  BMJ       Date:  1995-07-01

6.  Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.

Authors:  David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

Review 7.  Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

8.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

9.  A mixed methods study of HIV-related services in buprenorphine treatment.

Authors:  Hannah K Knudsen; Jennifer Cook; Michelle R Lofwall; Sharon L Walsh; Jamie L Studts; Jennifer R Havens
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-08-16

Review 10.  Interventions and approaches to integrating HIV and mental health services: a systematic review.

Authors:  Fiona Leh Hoon Chuah; Victoria Elizabeth Haldane; Francisco Cervero-Liceras; Suan Ee Ong; Louise A Sigfrid; Georgina Murphy; Nicola Watt; Dina Balabanova; Sue Hogarth; Will Maimaris; Laura Otero; Kent Buse; Martin McKee; Peter Piot; Pablo Perel; Helena Legido-Quigley
Journal:  Health Policy Plan       Date:  2017-11-01       Impact factor: 3.344

View more
  25 in total

1.  Stimulant Use and Study Protocol Completion: Assessing the Ability of Men Who Have Sex with Men to Collect Dried Blood Spots for Laboratory Measurement of HIV Viral Load.

Authors:  Richard A Teran; Adam W Carrico; Keith J Horvath; Martin J Downing; Mary Ann Chiasson; Suzan M Walters; Sabina Hirshfield
Journal:  Arch Sex Behav       Date:  2019-10-19

2.  Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.

Authors:  Jessica J Wyse; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Amy J Kennedy; Benjamin J Oldfield; Julie R Gaither; Kirsha S Gordon; Melissa Skanderson; Declan T Barry; Kendall Bryant; Stephen Crystal; Amy C Justice; Kevin L Kraemer
Journal:  AIDS Behav       Date:  2021-09-08

3.  Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States.

Authors:  Thibaut Davy-Mendez; Varada Sarovar; Tory Levine-Hall; Alexandra N Lea; Stacy A Sterling; Felicia W Chi; Vanessa A Palzes; Kendall J Bryant; Constance M Weisner; Michael J Silverberg; Derek D Satre
Journal:  Drug Alcohol Depend       Date:  2021-09-28       Impact factor: 4.492

4.  Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.

Authors:  Susan L Calcaterra; Marlene Martin; Richard Bottner; Honora Englander; Zoe Weinstein; Melissa B Weimer; Eugene Lambert; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

5.  Opioid agonist treatment improves progression through the HIV cascade of care among people living with HIV who use unregulated opioids.

Authors:  Stephen Juwono; M-J Milloy; JinCheol Choi; Nadia Fairbairn; Seonaid Nolan; M Eugenia Socías
Journal:  AIDS       Date:  2022-05-25       Impact factor: 4.632

6.  Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment.

Authors:  Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate
Journal:  Drug Alcohol Depend       Date:  2019-09-04       Impact factor: 4.492

7.  "You need money to get high, and that's the easiest and fastest way:" A typology of sex work and health behaviours among people who inject drugs.

Authors:  Shannon N Ogden; Miriam Th Harris; Ellen Childs; Pablo K Valente; Alberto Edeza; Alexandra B Collins; Mari-Lynn Drainoni; Matthew J Mimiaga; Katie B Biello; Angela R Bazzi
Journal:  Int J Drug Policy       Date:  2021-05-10

8.  Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV.

Authors:  Amy J Kennedy; Kathleen A McGinnis; Jessica S Merlin; E Jennifer Edelman; Adam J Gordon; P Todd Korthuis; Melissa Skanderson; Emily C Williams; Jessica Wyse; Benjamin Oldfield; Kendall Bryant; Amy Justice; David A Fiellin; Kevin L Kraemer
Journal:  J Subst Abuse Treat       Date:  2021-05-29

9.  A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study.

Authors:  E Jennifer Edelman; James Dziura; Yanhong Deng; Krysten W Bold; Sean M Murphy; Elizabeth Porter; Keith M Sigel; Jessica E Yager; David M Ledgerwood; Steven L Bernstein
Journal:  Contemp Clin Trials       Date:  2021-03-29       Impact factor: 2.226

10.  The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression.

Authors:  Jongyeon Kim; Catherine R Lesko; Anthony T Fojo; Jeanne C Keruly; Richard D Moore; Geetanjali Chander; Bryan Lau
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.